Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817988 | 0.85 | EPHX1 (0.54) | CHRM1LMNAEPHX1ALOX5HTR2A | |
| SCHEMBL4903451 | 0.85 | ALDH1A1 (0.53) | CHRM1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14797924 | 0.84 | KDM4E (0.43) | CHRM1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14798442 | 0.81 | ALDH1A1 (0.44) | CHRM1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3820588 | 0.81 | EPHX1 (0.55) | CHRM1LMNAEPHX1ALOX5HTR2A | |
| SCHEMBL14798226 | 0.80 | HTR2A (0.44) | CHRM1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4909459 | 0.80 | ALDH1A1 (0.40) | CHRM1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4903496 | 0.78 | PTGS1 (0.47) | KDM4EALDH1A1LMNASMN1; SMN2CCR2 | |
| SCHEMBL4901528 | 0.77 | BCHE (0.41) | KDM4EALDH1A1LMNASMN1; SMN2EPHX1 | |
| SCHEMBL22322971 | 0.76 | HTR2A (0.59) | CHRM1KDM4EALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493402-B2 | Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | Dompé S.p.A. (IT) | 2013-03-28 | — | — | US | disclosed |
| US-8288368-B2 | inhibitors of the C5a induced chemotaxis; psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion | DOMPÉ PHA.R.MA S.P.A. (IT) | 2012-10-16 | — | — | US | disclosed |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPE PHA.R.MA S.P.A. (IT) | 2008-02-21 | — | — | US | disclosed |
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | DOMPE S.P A. (IT) | 2005-04-14 | — | — | US | disclosed |
| EP-1366018-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.P.A. (IT) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002068377-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.p.A. (IT) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080067-A1 | Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells | C5AR2, C3AR1, C5AR1 | CHRM1 920/4885KDM4E 4458/4885ALDH1A1 689/4885 |
| US-20130079514-A1 | \"OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS\ | C5AR2, C3AR1, C5AR1 | CHRM1 1204/4885KDM4E 3935/4885ALDH1A1 1026/4885 |
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | C5AR2, C3AR1, C5AR1 | CHRM1 919/4885KDM4E 4525/4885ALDH1A1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.